IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
mattjeacock/iStock via Getty Images


Oncology focused biotech IDEAYA Biosciences (NASDAQ:IDYA) announced a clinical trial collaboration and supply agreement with Amgen (AMGN) on Wednesday to jointly evaluate two small molecule cancer agents against a certain form of solid tumors.
Accordingly, IDEAYA (IDYA) will test IDE397, its investigational, small molecule MAT2A inhibitor in combination with Amgen's (AMGN) AMG 193, an investigational small molecule MTA-cooperative inhibitor of PRMT5 in a Phase 1 trial targeted at MTAP-null solid tumors.

Per the terms, Amgen (AMGN) will sponsor the Phase 1 combination trial while IDEAYA (IDYA) delivers IDE397 drug supply to Amgen (AMGN).
The two companies will share the external costs related to the trial and will jointly develop the combination therapy.

Additionally, IDEAYA (IDYA) said Wednesday that the company delivered a certain data package to GSK (GSK) in connection with a monotherapy dose escalation study of an ongoing Phase 1/2 clinical trial for IDE397.